Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

Purpose

This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).

Condition

  • Hypertrophic Cardiomyopathy (HCM)

Eligibility

Eligible Ages
Between 18 Years and 90 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Documented history of oHCM with documented resting and/or Valsalva LVOT obstruction ≥ 50 mmHg who are currently receiving mavacamten commercially. - Echo-derived LVEF ≥55% on mavacamten at the time of enrollment. - Patient willing to consent for the study and undergo the study procedures.

Exclusion Criteria

  • Severe aortic stenosis or sub-aortic obstruction - Known infiltrative or storage disorder causing cardiac hypertrophy that mimics HCM (eg, Noonan syndrome, Fabry disease, amyloidosis). - History of LVEF <30%. - Paroxysmal atrial fibrillation (AF) with documented episode within 3 months. - Atrial fibrillation (paroxysmal or permanent) not on systemic anticoagulation. - Documented history of current obstructive coronary artery disease (> 70% stenosis in one or more epicardial coronary arteries) or documented history of myocardial infarction.

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Intervention Model Description
This is a single group study where patients will transition from mavacamten to aficamten following a standardized protocol
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
CMI
Switching from mavacamten on day 1 to aficamten starting at week 2.
  • Drug: Aficamten
    Patients will be switched from mavacamten to aficamten. Mavacamten will be stopped at enrollment, and aficamten started 2 weeks later.

Recruiting Locations

Oregon Health & Science University
Portland, Oregon 97239
Contact:
Ahmad Masri, MD
503-494-7551
masria@ohsu.edu

More Details

Status
Recruiting
Sponsor
Oregon Health and Science University

Study Contact

Ahmad Masri
503-494-7551
masria@ohsu.edu